<DOC>
	<DOCNO>NCT02947438</DOCNO>
	<brief_summary>This study aim comprehensively establish bio-similarity/bioequivalence EPIAO® EPREX® term 52-week comparison efficacy , safety immunogenicity . The targeted population anaemia patient end-stage chronic renal disease previously receive epoetin treatment haemodialysis .</brief_summary>
	<brief_title>Biosimilar Erythropoietin Anaemia Treatment ( Maintenance Phase Study )</brief_title>
	<detailed_description>This prospective , randomize , double blind , parallel group two arm study establish therapeutic equivalence , safety tolerability EPIAO® compare EPREX® treatment CKD relate anaemia subject haemodialysis . A total 264 subject randomize two group 1:1 ratio . Treatment arm A receive EPIAO® 1-3 time week , intravenously period 52 week treatment arm B receive EPREX , 1-3 time week , intravenously period 52 week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female subject age 18 75 year Subjects end stage renal disease ( CKD stage 5 ) hemodialysis epoetin treatment least 3 month prior screen Subjects haemoglobin 10 g/dl 12 g/dl Subjects clinically stable haemodialysis ( define clinically relevant change dialysis regimen and/or dialyzer ) least 3 month prior screen Subjects willing provide write informed consent Subjects serum ferritin ≥ 200 μg/L and/or transferrin saturation ≥ 20 % Subjects life expectancy least study period clinical judgment investigator Subjects anaemia due reason ( renal anaemia ) Subjects undergone blood transfusion within last 3 month Subjects major complication severe/chronic infection bleed aluminum toxicity Subjects suspect known pure red cell aplasia ( PRCA ) Subjects history aplastic anaemia Subjects uncontrolled diabetes ( fast blood glucose &gt; 240 mg/dl ) uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg , diastolic blood pressure &gt; 110 mm Hg ) Subjects know hypersensitivity ingredient investigational product , mammalian cellderived product human albumin product Subjects history seizure disorder Subjects hematological disorder Subjects hyperparathyroidism Subjects congestive heart failure and/or angina ( NYHA class III IV ) Subjects myocardial infarction stroke precede 6 month screen Subjects active malignancy previous 5 year Subjects gastrointestinal bleeding past 6 month Subjects immunosuppressive therapy previous 3 month Subjects active hepatitis B virus ( HBsAg ) ( positive HBsAg IgM antiHBc ) hepatitis C virus ( HCV ) ( positive AntiHCV antibody ) human immunodeficiency virus ( HIV ) Female subject pregnant , breastfeeding , plan pregnant study , woman childbearing potential ( woman surgically sterile i.e . bilateral tubal ligation , total hysterectomy &lt; 2 year post menopause ) use reliable method double contraception ( e.g . condom plus diaphragm , condom diaphragm plus spermicidal gel/foam , tubal ligation , stable dose hormonal contraception ) throughout study period Subjects participate trial involve erythropoietin past 6 month screening.Subjects currently participate participation investigational study within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Renal anemia</keyword>
	<keyword>Haemodialysis</keyword>
	<keyword>Maintenance phase</keyword>
</DOC>